Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced a further contract renewal with a major top-3 global pharmaceutical client extending its consultancy services to end of December 2021. This follows on from the announcement made on 22 December 2020 regarding the same client and demonstrates the repeat business that Venn Life Sciences continues to win from its long-term clients.
The Venn team in the Breda office in the Netherlands, will provide Chemistry, Manufacturing & Control consultancy services to this leading global pharmaceutical client for one of the client’s vaccine development programmes and follows the recently announced contract renewal for work on two of the client’s vaccine development programmes. This successful collaboration has been extended until end of December 2021.
Cathal Friel, Executive Chairman of Open Orphan, said: “We are delighted to enter 2021 with another contract signed by the Venn team in Breda with this top-3 global pharmaceutical client. Venn have been providing CMC support to this top tier company since 2012 and are pleased to be continuing to work with this client in their vaccine development programme.
“This contract demonstrates the depth of vaccine development knowledge across the Company and, in addition to being the world leader in vaccine and antiviral testing using human challenge clinical trials, reinforces our position as the go-to clinical research organisation for many other services required by both large pharma and vaccine developers at all stages of development.”
